Optimize Your CLD With Innovative And Flexible Transposase Technology

As a critical step to bringing safe, high-quality biotherapeutics to patients, cell line development (CLD) systems must adapt to accommodate increasingly complex biotherapeutics like mAbs, multispecific antibodies, fusion proteins, and antibody drug conjugates (ADCs). Without innovative cell expression systems designed to accommodate these molecules, sponsors will encounter major development bottlenecks and timelines will fall behind.

To empower CLD across a range of complex modalities, KBI Biopharma created their Selexis SUREtechnology platform, a suite of CLD services built with complex biologics in mind. Their latest offering is Selexis TranspoEase , a high-performance transposase enzyme-based mechanism that provides high titer and stability across formats. Download the full article to explore the possibilities of this new and flexible platform.